---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000917"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:00:34.857295+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma reports Q4 2024 net loss $5.9M ($0.54/share); cash $24M as pipeline advances

## Summary
- Net loss for Q4 2024 was $5.9M ($0.54 per share) vs $4.2M ($0.39) in Q4 2023; full year net loss $1.93/share vs $1.47.
- Cash, cash equivalents and marketable securities $24.0M as of Dec 31, 2024, down from $41.3M at Dec 31, 2023.
- HARMONIC trial lead-in cohort (LP-300) showed 86% clinical benefit rate and 43% ORR in never-smoker NSCLC; expansion cohort reinforcing trends.
- LP-184 received two FDA Fast Track Designations (GBM, TNBC) and three Rare Pediatric Disease Designations; Phase 1a on cohort 11.
- RADR platform surpassed 100B oncology data points; MD Anderson collaboration shows LP-184 synergy with anti-PD1 in TNBC preclinical models.

## SEC filing metadata
- accession: 0001641172-25-000917
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000164117225000917/0001641172-25-000917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000164117225000917/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000917
- JSON: https://secwatch.observer/filing/0001641172-25-000917.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000917.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.